Q4 and FY 2025 Financial Results and Business Highlights Conference call for investors and analysts 12 February 2026 4 2026 strategic priorities – driving long-term value creation | Execute high-impact launch for AQVESME | | --- | | (mitapivat) in thalassemia | | Potential to expand PK activation franchise into | | sickle cell disease and LR-MDS | | Unlock future value in hematology and other rare | | disease by advancing early-stage pipeline | | Ensure long-term sustainability through disciplined | | capit ...

Core Viewpoint - Lantheus Holdings, Inc. will host a conference call and webcast to discuss its financial and operating results for Q4 and the full year of 2025 on February 26, 2026 [1]. Group 1: Conference Call Details - The conference call and webcast will take place at 8:00 a.m. ET on February 26, 2026 [1]. - Participants can register online to access the conference call or webcast, with a recommendation to register fifteen minutes in advance to avoid delays [2]. - A replay of the webcast will be available approximately two hours after its completion and will be archived for at least 30 days [2]. Group 2: Company Overview - Lantheus is a leading company focused on radiopharmaceuticals, providing solutions that help clinicians in disease detection and management [3]. - The company has been in operation for 70 years and is headquartered in Massachusetts, with additional offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom [3].

Core Insights - Aspire Biopharma has filed a provisional patent application for a fast-acting sublingual powder formulation of ondansetron, the active ingredient in Zofran, aimed at providing rapid relief from nausea caused by cancer treatments [1] - The global ondansetron market was valued at approximately $1.4 billion in 2023 and is projected to grow to $2.4 billion by 2032, driven by increasing cancer incidences and surgical procedures [1] Company Developments - Aspire's new sublingual delivery system is designed to bypass the gastrointestinal tract, potentially reducing the onset of action from 30 minutes to just minutes, thus providing near-instant absorption [1] - The company plans to utilize the FDA's 505(b)(2) regulatory pathway to streamline clinical development and reduce time-to-market for its new formulation [1] Market Positioning - Ondansetron was the 53rd most prescribed medication in the U.S. in 2023, with over 12.5 million prescriptions, indicating significant market utilization [1] - The sublingual formulation specifically addresses the unmet need for patients who cannot swallow tablets due to severe vomiting or gastric irritation [1]

Core Insights - Pacira BioSciences, Inc. is focused on delivering innovative, non-opioid pain therapies and has highlighted new survey findings from the Voices for Non-Opioid Choices coalition regarding the impact of the Non-Opioids Prevent Addiction (NOPAIN) Act [1][2] Group 1: NOPAIN Act Impact - The NOPAIN Act, effective January 1, 2025, aims to prevent opioid addiction by increasing access to non-opioid pain management options for Medicare beneficiaries undergoing surgery [3] - A national survey of nearly 750 healthcare facilities showed that 85% of facility representatives were aware of the NOPAIN Act, and 52% had taken steps to increase the use of qualifying non-opioid options [7] - Over 80% of respondents reported a decrease in opioid prescribing immediately after surgery (83%) and at discharge (88%) due to the legislation [7] Group 2: Company Position and Products - Pacira's CEO emphasized that the NOPAIN Act is a significant step forward for expanding access to non-opioid pain management options, particularly for Medicare patients [3] - Pacira offers three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and iovera®, with a pipeline of clinical-stage assets including PCRX-201, a gene therapy for osteoarthritis of the knee [5] - The company is committed to transforming patient lives through innovative pain therapies and is actively tracking the impact of the NOPAIN Act on opioid reliance [3][5]

Core Viewpoint - Verrica Pharmaceuticals Inc. has appointed Chris Chapman as the new Chief Commercial Officer, aiming to enhance the commercialization of its products, particularly YCANTH for molluscum contagiosum and VP-315 for basal cell carcinoma [2][5]. Company Overview - Verrica Pharmaceuticals is focused on developing dermatology therapeutics for skin diseases that require medical interventions [5]. - The company's flagship product, YCANTH (VP-102), is the first FDA-approved treatment for molluscum contagiosum, affecting approximately 6 million people in the U.S., primarily children [4][5]. - YCANTH is also being developed for the treatment of common warts, addressing a significant unmet need in medical dermatology [5]. Leadership Appointment - Chris Chapman brings over 25 years of commercial experience in the pharmaceutical industry, having previously served as Chief Commercial Officer at Dermavant Sciences [2][3]. - His experience includes launching VTAMA for adult plaque psoriasis and leading the U.S. Prescription Business for Galderma [3]. Product Details - YCANTH is a proprietary drug-device combination that allows for precise topical dosing and is administered by healthcare professionals [4]. - The product has shown positive results in two Phase 3 clinical trials involving approximately 500 patients, demonstrating safety and efficacy [4]. - Approximately 250 million lives are eligible for YCANTH coverage by insurance, with commercially insured patients paying $25 per treatment visit [4]. Pipeline Development - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315, targeting non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [5].

Core Insights - Corbus Pharmaceuticals Holdings Inc. is set to present a corporate overview and engage in investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026 [1][2]. Company Overview - Corbus Pharmaceuticals is a clinical-stage company focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [2]. - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells to deliver a cytotoxic payload [2]. - CRB-601: An anti-integrin monoclonal antibody that inhibits the activation of TGFβ on cancer cells [2]. - CRB-913: A highly peripherally restricted CB1 inverse agonist designed for obesity treatment [2]. - Corbus is headquartered in Norwood, Massachusetts [2].

Core Insights - Eight Roads Ventures, backed by Fidelity International, plans to accelerate its investments in India, anticipating five to six deals this year, driven by a positive deal flow in the market [2][4] - The firm views India as the largest opportunity in Asia, surpassing China in terms of investment potential, particularly for the types of investments it is pursuing [3][7] - Since its entry into India in 2007, Eight Roads has invested approximately $1.6 billion across 80 businesses, with 11 of these achieving valuations over $500 million, and some exceeding $1 billion [4] Investment Focus - Eight Roads primarily invests in early growth and growth-stage companies, focusing on technology and healthcare sectors, with cheque sizes ranging from $5 million to $40 million [5] - The technology investments include fintech, enterprise, consumer, and increasingly, artificial intelligence-driven solutions, while healthcare investments cover life sciences, advanced manufacturing, and pharmaceuticals [5][6] Market Trends - Healthcare has emerged as the largest sector for private investments in India, evolving from the fourth or fifth largest sector in previous years, with a notable increase in innovative companies in pharma and MedTech [6] - The firm emphasizes the importance of a robust digital infrastructure and payments network in India as foundational elements for future investments [7] Exit Strategies - Eight Roads has successfully executed secondary transactions, including a $50 million stake sale in MoEngage, Whatfix, and Shadowfax, indicating a trend towards increasing secondary market activity [9][10] - The firm believes that secondary transactions will remain a significant part of venture capital operations, providing opportunities for returning capital to limited partners and de-risking investments over time [11][12]

Core Insights - Karyopharm Therapeutics reported its financial results for Q4 and full year 2025, highlighting significant revenue growth and upcoming clinical milestones for its lead product, XPOVIO (selinexor) [1][2] Financial Performance - Total revenue for Q4 2025 was $34.1 million, up from $30.5 million in Q4 2024, while full-year revenue reached $146.1 million compared to $145.2 million in 2024 [2][5] - U.S. net product revenue for XPOVIO was $32.1 million in Q4 2025, compared to $29.3 million in Q4 2024, and $114.9 million for the full year, up from $112.8 million in 2024 [2][5] - The company expects total revenue for 2026 to be between $130 million and $150 million, with U.S. XPOVIO net product revenue projected between $115 million and $130 million [1][2] Research and Development Highlights - The Phase 3 SENTRY trial for myelofibrosis is expected to report top-line data in March 2026, with the potential to introduce the first combination therapy in this area [1][3] - The Phase 3 XPORT-EC-042 trial for endometrial cancer is on track to report top-line data in mid-2026, focusing on a biomarker-driven patient population [1][3] - Enrollment in the Phase 3 XPORT-MM-031 trial for multiple myeloma was completed in Q4 2024, with top-line data anticipated in the second half of 2026 [1][3] Operational Objectives - The company aims to maintain its commercial foundation in the competitive multiple myeloma market and drive increased revenues for XPOVIO [2][3] - Karyopharm plans to support global launches of XPOVIO in ex-U.S. territories following regulatory approvals [2][3] Market Context - Myelofibrosis affects approximately 20,000 patients in the U.S., with significant unmet needs in treatment options [3] - Endometrial cancer is the most common gynecologic malignancy in the U.S., with rising incidence and mortality rates, highlighting the need for effective therapies [3][4]

Core Viewpoint - The strategic agreement between CC Pharma and Smartway Pharmaceuticals aims to enhance the distribution of pharmaceutical products in the UK, marking a significant step in Tilray's European medical expansion strategy [1][2][4]. Group 1: Agreement Details - CC Pharma and Smartway will collaborate to expand parallel import and specialist pharmaceutical supply in the UK, utilizing Smartway's national distribution infrastructure and CC Pharma's European procurement capabilities [2][4]. - The UK pharmaceutical market is valued at nearly £1 billion, positioning Tilray and CC Pharma to improve access and supply reliability through established healthcare channels [3][4]. Group 2: Strategic Importance - The UK is identified as a priority market within Tilray's international medical strategy, with the agreement expected to enhance access to medicinal products and support long-term growth in Europe [4][5]. - The partnership is built on a longstanding relationship since 2009, focusing on cross-border pharmaceutical collaboration and supply chain execution [4][5]. Group 3: Leadership Insights - Rajnish Ohri, President of International at Tilray Brands, emphasized the agreement's role in broadening access to medicinal products and embedding Tilray into the UK health system [4]. - Mathias Bossen, Managing Director of CC Pharma, highlighted the importance of leveraging Smartway's national network to enhance supply reliability for pharmacy and hospital partners [5].

Corporate Presentation February 2026 Confidential and Proprietary Forward looking statements Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations, estimates, assumptions, and projections regarding our future operating results and financial performance, including our expectations for profitability in 2027, anticipated cost or expense management, including the company's expectations rel ...